Growth of Public Companies in AI-Driven Drug Discovery
ANT Anthropic PBC
$96.86 +16.70%
View chart & analysis → - 1AI is becoming part of the drug discovery process, and several public companies are finding opportunities in this field.
- 2Anthropic recently began a roadshow for its Class A common stock initial public offering (IPO).
- 3Schrödinger announced in its Q3 2026 earnings report that its annual contract value increased 17% year-over-year to $44.7 million.
So what's the key point?
Companies using artificial intelligence to create medicines are growing. Schrödinger is finding opportunities as its contract value increased by 17%.
Source FinanceWire · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.